At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Gefitinibdrug
Likely dose
Gefitinib 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198)
In Brief
A Phase 2 clinical trial evaluating Gefitinib for Salivary Gland Cancer. Completed, enrolled 37 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSalivary Gland Cancer
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2004
First PostedJul 2007
Primary CompletionSep 2016
TodayJul 2026
First PostedJul 30, 2007
Enrollment StartMay 1, 2004
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 12.3 yearsPosted 18.9 years ago
Interventions
Gefitinibdrug
250 mg by mouth once a day, every day, at about same time in morning.